In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Deal Highlights Bristol's Biotech Swagger

Executive Summary

Bristol-Myers' asset sale continued with a huge deal with Pfizer in April. The move demonstrates BMS' biotech-like strategy of monetizing late-stage assets to hedge risk.

Related Content

Pharma: Serious About Change?
Pfizer Restructures for a More Flexible Future
Pharma's Strategic Divide: Focus or Diversify
Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
Pharmaceutical Strategic Alliances: Sharing and Optimizing Risk
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
Reviewing Five Years of Big Pharma's Biotech Acquisitions
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
Best Laid Plans: Pfizer's Torcetrapib Tanks
Generic Plavix: As Bristol Swoons, Broad Implications


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts